89Zr-DFO-trastuzumab for Oesophago-gastric Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Oesophago-gastric Cancer
89Zr-DFO-trastuzumab - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to deliver cancer drugs. The first group of patients is helping the investigators learn when to take pictures and how to monitor the drug in the blood. The second group of patients will just receive the injection and be asked to return for a picture 5-8 days later.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Oesophago-gastric Cancer

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: 2 years

2 years
Toxicity
feasibility
metabolite analysis

Trial Safety

Safety Progress

1 of 3

Other trials for Oesophago-gastric Cancer

Trial Design

1 Treatment Group

PET Imaging With 89Zr-DFO-Trastuzumab
1 of 1
Experimental Treatment

36 Total Participants · 1 Treatment Group

Primary Treatment: 89Zr-DFO-trastuzumab · No Placebo Group · N/A

PET Imaging With 89Zr-DFO-TrastuzumabExperimental Group · 2 Interventions: 89Zr-DFO-trastuzumab, PET imaging · Intervention Types: Radiation, Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET imaging
2005
Completed Phase 3
~630

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,311 Total Patients Enrolled
5 Trials studying Oesophago-gastric Cancer
160 Patients Enrolled for Oesophago-gastric Cancer
Neeta Pandit-Taskar, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
6 Previous Clinical Trials
239 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
waits 90 minutes for emergency surgery A registered patient at MSKCC waited for emergency surgery for 90 minutes.
Pathologically or cytologically confirmed metastatic or primary esophagogastric cancer
Patients must have a measurable or evaluable disease that has not been previously radiated and requires a clinically indicated imaging evaluation within 4 weeks prior to study entry
Patients will be asked to consent to provide access to data obtained from molecular analysis of archived tumor tissue
A negative pregnancy test will be performed on any female patient of childbearing potential within one week before the administration of radioactive material.
The patient has a life expectancy of at least three months.
The willingness to use birth control while on study was high in both groups.
The subject has a Karnofsky Performance Score ≥ 60, indicating that he/she is able to carry out normal activities.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: October 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.